OPKO Health, Inc. (NASDAQ:OPK) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its stake in shares of OPKO Health, Inc. (NASDAQ:OPK - Free Report) by 142.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,490,992 shares of the biotechnology company's stock after buying an additional 876,272 shares during the quarter. Assenagon Asset Management S.A. owned approximately 0.21% of OPKO Health worth $2,227,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in OPK. CIBC Asset Management Inc lifted its stake in OPKO Health by 79.1% in the second quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company's stock worth $25,000 after acquiring an additional 8,978 shares during the last quarter. Virtu Financial LLC acquired a new stake in shares of OPKO Health in the 1st quarter valued at $26,000. Algert Global LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth $44,000. Headlands Technologies LLC acquired a new position in shares of OPKO Health during the first quarter worth $47,000. Finally, Private Advisor Group LLC increased its holdings in OPKO Health by 242.7% in the third quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company's stock valued at $53,000 after buying an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In related news, major shareholder Opko Health, Inc. sold 12,994 shares of the stock in a transaction on Tuesday, August 6th. The stock was sold at an average price of $29.35, for a total transaction of $381,373.90. Following the completion of the sale, the insider now directly owns 2,971,570 shares of the company's stock, valued at $87,215,579.50. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In the last ninety days, insiders have sold 262,605 shares of company stock worth $8,635,020. 47.26% of the stock is currently owned by insiders.

OPKO Health Stock Performance

OPKO Health stock remained flat at $1.51 during midday trading on Friday. 2,504,503 shares of the company's stock traded hands, compared to its average volume of 7,061,807. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The stock has a market cap of $1.05 billion, a PE ratio of -4.63 and a beta of 1.63. OPKO Health, Inc. has a 52 week low of $0.85 and a 52 week high of $1.75. The business has a 50-day moving average price of $1.53 and a 200 day moving average price of $1.41.

OPKO Health (NASDAQ:OPK - Get Free Report) last announced its earnings results on Wednesday, August 7th. The biotechnology company reported ($0.01) earnings per share for the quarter, topping the consensus estimate of ($0.09) by $0.08. The business had revenue of $182.20 million during the quarter, compared to the consensus estimate of $184.70 million. OPKO Health had a negative net margin of 33.79% and a negative return on equity of 17.67%. The business's quarterly revenue was down 31.3% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.03) earnings per share. On average, equities research analysts forecast that OPKO Health, Inc. will post -0.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

OPK has been the topic of a number of recent analyst reports. StockNews.com upgraded OPKO Health to a "sell" rating in a report on Saturday, July 27th. HC Wainwright reiterated a "buy" rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Piper Sandler reissued an "overweight" rating and issued a $3.00 target price on shares of OPKO Health in a report on Tuesday, September 17th. Finally, Barrington Research restated an "outperform" rating and set a $2.25 price target on shares of OPKO Health in a research note on Friday, September 20th.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.